NRx Pharmaceuticals Transitions to Commercial Stage Following FDA Approval and Q3 2026 Earnings
NRx Pharmaceuticals (NRXP) has officially transitioned from a clinical-stage company to a commercial biopharmaceutical entity following the October 29, 2026, FDA approval of its preservative-free ketamine drug-device combination. Utilizing blow-fill-seal technology, the new packaging offers significant unit cost savings compared to traditional glass vials and enhances manufacturing throughput capacity to up to 5 million units per month. Financially, the company reported Q3 net revenue of $1.2 million, driven by the expansion of its HOPE Therapeutics clinical operations. While the company recorded a quarterly net loss of $2.2 million, this represents an improvement over the prior comparable quarter due to debt restructuring and accounting adjustments. NRx is also leveraging a $11.2 million DARPA contract for the SPARC-TMS clinical trial targeting depression and PTSD in military populations.